Sub-threshold Photocoagulation of Diabetic Macular Oedema

Status Withdrawn

Clinical Trial Summary

Topcon's Endpoint Management (EM) is a new software from the Pascal® laser which allows us to decrease the intensity of the burns (invisible burns) showing some landmarks with normal intensity so the investigators can see the area which has been treated. The Pascal® system with EM utilizes 577nm laser wavelength compared to the 532nm laser wavelength which was utilized in previous Pascal® laser studies.

This study aims to demonstrate that 577nm Pascal® with EM has the same efficacy and effectiveness as 532nm Pascal® in the treatment of diabetic macular oedema.

Clinical Trial Description

Diabetic macular oedema (DMO) remains the most common cause of visual loss in diabetic patients and affects around 29% of diabetic patients with 20 or more years of disease. The Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated a significant benefit of laser photocoagulation for the treatment of clinically significant macular oedema, reducing the incidence of vision loss by approximately 50% at 3 years' follow-up.

The original ETDRS photocoagulation technique was adopted throughout the world and gradually modified through the years. Despite the great improvements, loss of central vision, paracentral scotoma and decreased color vision are some adverse events that can still occur, mostly caused by the progressive enlargement of the laser scars consequent to the visible burn of conventional laser photocoagulation.

New strategies have been developed for laser treatments that minimize the chorioretinal damage while maintaining at least similar treatment efficacy.

And numerous clinical studies have been conducted with subvisible laser treatments. However, the lack of a visible endpoint makes it difficult for the treating physician to know which retinal areas have been treated in order to avoid retreatment and also to be confident that the desired target tissue had been treated.

Topcon's Endpoint Management (EM) is a new software from the Pascal® laser which allows us to decrease the intensity of the burns (invisible burns) showing some landmarks with normal intensity so the investigators can see the area which has been treated.

The Pascal® system with EM utilizes 577nm laser wavelength compared to the 532nm laser wavelength which was utilized in previous Pascal® laser studies.

This study aims to demonstrate that 577nm Pascal® with EM has the same efficacy and effectiveness as 532nm Pascal®. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02309476
Study type	Interventional
Source	Manchester University NHS Foundation Trust
Contact
Status	Withdrawn
Phase	N/A
Start date	October 2012
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04576689` - Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - A Sustained, Low Dose Dexamethasone Therapy	Phase 2
Completed	`NCT02554747` - Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa	N/A
Terminated	`NCT02207712` - Noctura400 Treatment for Diabetic Retinopathy (CANDLE)	N/A
Completed	`NCT02457884` - Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular Oedema	N/A
Completed	`NCT00148330` - Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study	Phase 2/Phase 3
Completed	`NCT03495765` - To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus	Phase 3
Completed	`NCT00167518` - Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)	Phase 2/Phase 3
Completed	`NCT01787669` - Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema	Phase 2
Completed	`NCT01175070` - Intravitreal Macugen for Ischaemic Diabetic Macular Oedema	Phase 4
Terminated	`NCT00427986` - Clinical Study of the Effect of Intravenous Galactose on Diabetic Macular Oedema	N/A
Completed	`NCT00333671` - Quantification of Rising the Osmotic Pressure in Diabetic Intraretinal Fluid Accumulation (Diabetic Macular Oedema)	N/A
Completed	`NCT02731911` - Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
Completed	`NCT00148265` - A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema	Phase 2/Phase 3
Completed	`NCT02181400` - Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Sub-threshold Photocoagulation of Diabetic Macular Oedema — MEM

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms